Cluster Headache (Episodic)
Highly investigational use for episodic cluster headache between attack cycles; very limited anecdotal data, not for active attacks.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for cluster headache. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
- What evidence exists?
- Tier C (investigational). There are no published controlled trials. Cluster headache is one of the most painful conditions known and requires aggressive evidence-based therapy: acute attacks with high-flow oxygen via non-rebreather mask, subcutaneous sumatriptan, or intranasal zolmitriptan (the highest-evidence acute therapies); transitional prevention with corticosteroid taper or occipital nerve block; preventive therapy with verapamil (first-line), lithium, topiramate, or galcanezumab; non-invasive vagal nerve stimulation (FDA-cleared for episodic cluster); and sphenopalatine ganglion stimulation or occipital nerve stimulation for refractory cases. Onset of an acute attack is a medical emergency for symptom control.
- Main risks
- Bleeding from each bite site for 6 to 24 hours after detachment
- Bruising over the temporal or periorbital region for 5 to 10 days
- Local skin or, rarely, Aeromonas hydrophila infection
- Allergic reaction to leech saliva (uncommon)
- TRIGGER RISK: any stimulus can trigger a cluster attack during a cluster period
- Delay of high-flow oxygen, sumatriptan, verapamil, and other proven therapies (a delay in cluster is intolerable pain)
- Misdiagnosis - clusters are sometimes confused with secondary causes (pituitary tumor, carotid dissection) that need urgent workup
- Placement near temporal artery in age over 50 risks giant cell arteritis being missed
- Who should not consider this
- Patients in an active cluster period who have not optimized acute (oxygen, triptans) and preventive (verapamil) therapy
- Patients with red-flag features (focal neurological signs, autonomic features outside attacks, age over 50 new-onset)
- Patients with suspected secondary causes (pituitary tumor, AVM, carotid dissection)
- Patients on anticoagulants, with hemophilia, or with anemia
- Patients with active dermatitis or broken skin at planned placement sites
- Patients on monoamine oxidase inhibitors or with cardiovascular contraindications to triptans (different issue, but triptan optimization first)
- What to ask your clinician
- Am I receiving high-flow oxygen (12 to 15 L/min via non-rebreather) for acute attacks?
- Have I tried subcutaneous sumatriptan or intranasal zolmitriptan?
- Am I on verapamil titrated to adequate dose for prevention?
- Have I had MRI brain to rule out secondary causes (pituitary tumor, AVM, carotid dissection)?
- Am I a candidate for occipital nerve block, sphenopalatine ganglion stimulation, or non-invasive vagal nerve stimulation?
- Why is leech therapy being considered given the highly effective evidence-based options for cluster?
- What is the practitioner's plan if I have a cluster attack during or after a session?
- When to seek urgent care
- Thunderclap (worst-of-life) headache, sudden severe headache (possible subarachnoid hemorrhage - 911)
- Headache with fever, stiff neck, photophobia, or altered mental status (possible meningitis)
- Headache with focal neurological deficit, vision change, speech difficulty, or seizure
- Sudden severe pain with neck stiffness and Horner syndrome features (possible carotid dissection)
- Cluster attacks that do not respond to oxygen or triptans
- Bleeding from a bite site lasting more than 24 hours
- Hives, facial or throat swelling, or breathing difficulty
What this does NOT mean
- This is not FDA-cleared for cluster headache.
- No controlled trials support efficacy; cluster headache responds dramatically to high-flow oxygen, sumatriptan, and verapamil.
- It does not abort an acute cluster attack; high-flow oxygen and triptans do.
- It does not prevent cluster attacks; verapamil, lithium, topiramate, and galcanezumab do.
- Misdiagnosis of secondary causes (pituitary, AVM, carotid dissection) can be catastrophic if delayed.
Safety cross-references
Clinical Profile
- Category
- Neurological
- ICD-10
- G44.001, G44.009, G44.019
- Safety tier
- Medium
Evidence Summary
Cluster headache is conventionally managed with high-flow oxygen and subcutaneous sumatriptan for acute attacks, and verapamil, lithium, or galcanezumab for prevention. Occipital nerve blocks and non-invasive vagus nerve stimulation are second-line preventives. No controlled trial or case series of leech therapy for cluster headache was identified. The only clinical report found is a single-patient case report of episodic cluster headache (Bhat 2024) in which leech therapy was combined with nasal medicated ghee (nasya) and oral Ayurvedic medicines, so the effect of the leeches cannot be separated from the rest of the regimen; any use is investigational and not supported by controlled data. Hirudotherapy must never be applied during an active attack; conventional acute therapy (oxygen, triptan) is non-negotiable.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Active cluster attack (oxygen and triptan are emergent therapy)
- Secondary cluster from undiagnosed structural lesion
- Trigeminal autonomic cephalgia of unclear subtype
Related Conditions
Migraine
Investigational use; the only clinical studies found in journal searches are a 7-patient case series and a 26-patient non-randomized pilot (older reports are described in “What the books describe”), and the proposed mechanism is hypothetical.
Trigeminal Neuralgia (Classical / Idiopathic)
Investigational use for classical trigeminal neuralgia refractory to first-line carbamazepine; only two single-patient case reports were located in journals (see also “What the books describe”).
Tension-Type Headache
Investigational use for chronic tension-type headache; no study for this headache type was identified, and the proposed mechanism (muscle tension, venous congestion) is untested.
Cervical Radiculopathy
Investigational use for cervical radiculopathy; no verifiable published trial specific to this indication.